Trial Profile
A Multicenter, Randomized, Double-Blind, Controlled Phase 3, Efficacy And Safety Study Of Sunitinib (SU011248) In Patients With Advanced/Metastatic Non-Small Cell Lung Cancer Treated With Erlotinib
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Dec 2021
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary) ; Erlotinib
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Pfizer
- 23 May 2018 Results presented at the 23rd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
- 10 Aug 2017 The study has been discontinued in Belgium according to European Clinical Trials Database record.
- 02 Jun 2017 Results assessing application of electronic medical records (EMRs) as a virtual comparator arm, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology